Which anti‑diabetic therapy is appropriate for a patient with acute kidney injury (AKI) and acute myocardial infarction (MI)?

Anti-Diabetic Therapy in Acute Kidney Injury (AKI) and Myocardial Infarction (MI)

Insulin is the safest and most appropriate anti-diabetic therapy for patients with acute kidney injury and acute myocardial infarction, with a target glucose range of 110-180 mg/dL. 1, 2, 3

Immediate Management: Stop Metformin

• Metformin must be temporarily discontinued immediately in patients with AKI and serious intercurrent illness (including MI), regardless of baseline kidney function 1, 2, 4
• This is a "sick-day rule" that applies to all patients with GFR <60 mL/min/1.73 m² who develop serious illness that increases AKI risk 1, 2
• Metformin carries risk of lactic acidosis when kidney function is acutely compromised, even though chronic use at stable kidney function is relatively safe 1

First-Line Therapy: Insulin

Insulin should be initiated as the primary glucose-lowering agent in this acute setting for several critical reasons:

• Insulin is the only anti-diabetic agent without renal excretion concerns and can be safely titrated regardless of kidney function 3
• Target blood glucose of 110-180 mg/dL (preprandial <110 mg/dL, maximum 180 mg/dL) reduces mortality in MI patients with diabetes 3
• Intensive insulin therapy in diabetic MI patients reduced long-term mortality by 25% in landmark trials 3
• Insulin allows precise, rapid titration in the hemodynamically unstable post-MI period 3

SGLT2 Inhibitors: Contradictory Evidence

The role of SGLT2 inhibitors in this setting is complex and controversial:

Potential Benefits:

• Pre-clinical studies show SGLT2 inhibitors (empagliflozin, canagliflozin) may actually protect against MI-induced AKI in diabetic rats through β-hydroxybutyrate-mediated suppression of oxidative stress 5, 6
• These agents reduced renal injury markers (NGAL, KIM-1) and NOX expression in animal models 5, 6

Significant Risks:

• Real-world pharmacovigilance data shows canagliflozin has the highest reporting odds ratio (3.70) for AKI among SGLT2 inhibitors, with median onset 72 days after initiation 7
• SGLT2 inhibitors cause dose-dependent osmotic diuresis and volume depletion, increasing AKI risk particularly when combined with diuretics 8
• Risk of euglycemic diabetic ketoacidosis is elevated in acute illness, fasting states, and surgical settings 8

Clinical Recommendation: SGLT2 inhibitors should be held during the acute AKI/MI period due to volume depletion and ketoacidosis risks, but can be considered for resumption after stabilization given their long-term cardiovascular and renal benefits 8, 7

DPP-4 Inhibitors: Avoid in This Setting

• Sitagliptin in diabetic patients with CKD after MI was associated with increased risk of recurrent MI (HR 1.73) and need for repeat revascularization (HR 1.43) 9
• While not associated with increased mortality or heart failure hospitalization, the increased MI recurrence risk makes this class inappropriate in acute post-MI settings 9

Other Agents to Discontinue

Temporarily stop these medications during acute AKI/MI:

• ACE inhibitors and ARBs (despite long-term benefits, they reduce glomerular filtration acutely and risk hyperkalemia) 10, 1, 2
• Diuretics (volume depletion risk) 1, 2
• NSAIDs (nephrotoxic) 1, 2
• Digoxin (renally excreted, narrow therapeutic window) 1, 2

Monitoring Requirements

• Check serum creatinine and electrolytes within 7-14 days after any medication changes 11
• Monitor blood glucose every 1-4 hours during insulin titration 3
• Assess volume status and blood pressure closely if considering SGLT2 inhibitor resumption 8
• Monitor for hyperkalemia if restarting ACE inhibitors/ARBs after AKI resolution 11

Transition Strategy After Stabilization

Once AKI has resolved (creatinine returning toward baseline, stable for 48-96 hours) and the patient is hemodynamically stable:

1. Reassess GFR to determine which agents are appropriate 1, 2
2. Consider restarting metformin if GFR ≥45 mL/min/1.73 m² 1, 2, 4
3. Initiate SGLT2 inhibitor for long-term cardio-renal protection if GFR >25 mL/min/1.73 m² and volume status is optimized 12, 8
4. Restart ACE inhibitor or ARB for post-MI cardioprotection and albuminuria management once volume status is stable 13, 11

Critical Pitfalls to Avoid

• Do not continue metformin during acute illness—this is the most common and dangerous error 1, 2
• Do not use DPP-4 inhibitors in the acute post-MI period given increased recurrent MI risk 9
• Do not combine ACE inhibitor + ARB + aldosterone antagonist—this triple combination is potentially harmful 13
• Do not assume SGLT2 inhibitors are safe in acute volume-depleted states despite their long-term benefits 8, 7